Intravitreal VEGF-inhibitors: Is Avastin® a generic substitute for Lucentis®?

Acta Ophthalmologica Scandinavica

Volumn 85, Issue 1, 2007, Pages 2-4

  la Cour, Morten ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GENERIC DRUG; PEGAPTANIB; PLACEBO; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ARTERY EMBOLISM; ARTERY THROMBOSIS; CLINICAL TRIAL; COLON CANCER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DISEASE ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; ENDOPHTHALMITIS; FLUORESCENCE ANGIOGRAPHY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; SINGLE DRUG DOSE; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUGS, GENERIC; HUMANS; INJECTIONS; MACULAR DEGENERATION; THERAPEUTIC EQUIVALENCY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 33846428067     PISSN: 13953907     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2006.00869.x     Document Type: Editorial

References (29)

1. Abraham P, Yue H & Shams N (2006): PIER: Year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age-related macular degeneration. Abstract, Cannes Retina Festival, 9-13 September 2006, Cannes, France.
2. Avery RL, Pearlman J, Pieramici DJ et.al. (2006a): Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695-1715.
3. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA & Giust MJ (2006b): Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372.
4. Bakri SJ, Snyder MR, Pulido JS, Reid J & Singh RJ (2006): Pharmacokinetics of intravitreal bevacizumab (Avastin). Abstract, Cannes Retina Festival, 9-13 September 2006, Cannes, France.
5. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP & Noureddin BN (2006): Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142: 1-9.
6. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR & Khan S (2006): Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26: 871-876.
7. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP & Schneider S (2006): Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
8. Buch H, Nielsen NV, Vinding T, Jensen GB, Prause JU & la Cour M (2005): 14-year incidence, progression, and visual morbidity of age-related maculopathy: The Copenhagen City Eye Study. Ophthalmology 112: 787-798.
9. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr & Scott IU (2006): Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 47: 4569-4578.
10. la Cour M, Kiilgaard JF & Nissen MH (2002): Age-related macular degeneration: Epidemiology and optimal treatment. Drugs Aging 19: 101-133.
11. Ferrara N, Damico L, Shams N, Lowman H & Kim R (2006): Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26: 859-870.
12. Fung AE, Rosenfeld PJ, Puliafito CA, Michels S, Lalwani GA & Feuer WJ (2006a): One year results of Ahe PRONTO study: an OCT-guided variable-dosing regimen with ranibizumab (Lucentis) in neovascular AMD. Abstract, Combined Meeting of Club Jules Gonin and The Retina Society, 15-20 October 2006, Cape Town, South Africa.
13. Fung AE, Rosenfeld PJ & Reichel E (2006b): The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344-1349.
14. Gaudreault J, Fei D, Rusit J, Suboc P & Shiu V (2005): Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46: 726-733.
15. Gordon MS, Margolin K, Talpaz M et.al. (2001): Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843-850.
16. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M & Guyer DR (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
17. Grisanti S, Tatar O, Gelisken F, Eckardt C, Lucke K & Bartz-Schmidt KU (2006): Histopathologic evaluation of choroidal neovascular membranes following intraitreal bevacizumab injection. Abstract, Combined Meeting of Club Jules Gonin and The Retina Society, 15-20 October 2006, Cape Town, South Africa.
18. Hurwitz H, Fehrenbacher L, Novotny W et.al. (2004): Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
19. Meyer CH, Mennel S, Schmidt JC & Kroll P (2006): Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 90: 1207-1208.
20. Ratner M (2004): Genentech discloses safety concerns over Avastin. Nat Biotechnol 22: 1198.
21. Rich RM, Rosenfeld PJ, Puliafito CA et.al. (2006): Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495-511.
22. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY & Kim RY (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
23. Rosenfeld PJ, Moshfeghi AA & Puliafito CA (2005): Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36: 331-335.
24. Shahar J, Avery RL, Heilweil G et.al. (2006): Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26: 262-269.
25. Silva PJ, Jorge R, Alves CR, Rodrigues ML & Scott IU (2006): Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84: 556-557.
26. Spaide RF, Laud K, Fine HF et.al. (2006): Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26: 383-390.
27. Spandau UH, Ihloff AK & Jonas JB (2006): Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 84: 555-556.
28. Wang Y, Fei D, Vanderlaan M & Song A (2004): Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7: 335-345.
29. Xu L, Jumbe N, Eppler S, Lu J, Damico L & Joshi A (2006): Population pharmacokinetics of ranibizumab in patients with age-related macular degeneration. Abstract, 2006 AAPS Meeting, 29 October-2 November 2006, San Antonio, TX, USA.